Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

VYNE Relative to the S&P 500

VYNE Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the VYNE Therapeutics, Inc. (NASD:VYNE) seasonal charts above shows that a Buy Date of December 29 and a Sell Date of April 3 has resulted in a geometric average return of 2.64% above the benchmark rate of the S&P 500 Total Return Index over the past 6 years. This seasonal timeframe has shown positive results compared to the benchmark in 4 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 6 years by an average of 63.14% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

A word of caution: Only 6 years of data is available for shares of VYNE, perhaps insufficient to create a seasonal profile that accurately gauges the seasonal tendencies influencing the investment. Ideally, while 20 years is preferred, at least 10 years of data is required to perform a seasonal analysis that is considered to be reliable for future seasonal periods.

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary,?innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.

To download VYNE seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: VYNE